logo

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (2024 - 2029)

The Dipeptide Peptidase 4 Inhibitors Market is projected to experience growth over the forecast period, driven by factors such as the increasing prevalence of diabetes and the impact of the COVID-19 pandemic. These inhibitors play a crucial role in managing high blood glucose levels, particularly in type 2 diabetes patients, and have shown potential benefits in reducing COVID-19 complications. Technological advancements in drug formulations are also contributing to the market's expansion.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Inhibitors Research DPP4 Market Market Size

Market Size of Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Summary
Study Period 2018 - 2029
Market Size (2024) USD 11.59 Billion
Market Size (2029) USD 13.30 Billion
CAGR (2024 - 2029) 2.78 %
Fastest Growing Market Latin America
Largest Market Asia-Pacific
Market Concentration Medium

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis

The Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 11.59 billion in 2024, and is expected to reach USD 13.30 billion by 2029, growing at a CAGR of 2.78% during the forecast period (2024-2029).

The COVID-19 pandemic positively impacted the Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. In the current crisis, type 2 diabetes patients are at much higher risk.

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.

According to International Diabetes Federation (IDF), the adult diabetes population is approximately 537 million currently, and this number is going to increase by 643 million in 2030. Technological advancements have increased over the period leading to several modifications either in the DPP-4 Inhibitor drugs or the formulations being developed.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Segmentation

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a pharmacological class of drugs for treating Type 2 diabetes. They help to control glycemia by increasing the levels of active incretins. The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is segmented into drugs and geography. The report offers the value (in USD) and volume (in units) for the above segments. 

Drugs
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia (Alogliptin)
Galvus (Vildagliptin)
Others
Geography
North America
United States
Canada
Rest of North America
Europe
France
Germany
Italy
Spain
United Kingdom
Russia
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Asia-Pacific
Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Middle East and Africa
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region Or Segment?
Customize Now

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size Summary

The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is poised for growth over the forecast period, driven by the increasing prevalence of type 2 diabetes and the rising demand for effective glucose-lowering medications. DPP-4 inhibitors play a crucial role in managing blood sugar levels by enhancing insulin and GLP-1 secretion, making them a popular choice for diabetes treatment. The market's expansion is further supported by technological advancements leading to drug modifications and new formulations. The COVID-19 pandemic has also positively impacted the market, as individuals with diabetes are at higher risk of severe COVID-19 complications, thereby increasing the demand for DPP-4 inhibitors. The market is characterized by a mix of global and regional players, with significant competition and the presence of generic drug manufacturers, particularly in regions like China.

The market landscape is fragmented, with major pharmaceutical companies such as AstraZeneca, Merck, Boehringer Ingelheim, Novartis, and others actively participating. These companies are focusing on expanding their presence in key markets while navigating challenges such as slow economic growth and increased competition. The introduction of cost-effective drug combinations and pricing regulations in countries like India further highlights the dynamic nature of the market. As the adult diabetes population continues to grow, the demand for DPP-4 inhibitors is expected to rise, supported by their role as a complementary therapy to metformin and other diabetes medications. This growth trajectory is anticipated despite the challenges posed by market maturity and regulatory environments in various regions.

Explore More

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drugs

      1. 2.1.1 Januvia (Sitagliptin)

      2. 2.1.2 Onglyza (Saxagliptin)

      3. 2.1.3 Tradjenta (Linagliptin)

      4. 2.1.4 Vipidia (Alogliptin)

      5. 2.1.5 Galvus (Vildagliptin)

      6. 2.1.6 Others

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Rest of North America

      2. 2.2.2 Europe

        1. 2.2.2.1 France

        2. 2.2.2.2 Germany

        3. 2.2.2.3 Italy

        4. 2.2.2.4 Spain

        5. 2.2.2.5 United Kingdom

        6. 2.2.2.6 Russia

        7. 2.2.2.7 Rest of Europe

      3. 2.2.3 Latin America

        1. 2.2.3.1 Mexico

        2. 2.2.3.2 Brazil

        3. 2.2.3.3 Rest of Latin America

      4. 2.2.4 Asia-Pacific

        1. 2.2.4.1 Japan

        2. 2.2.4.2 South Korea

        3. 2.2.4.3 China

        4. 2.2.4.4 India

        5. 2.2.4.5 Australia

        6. 2.2.4.6 Vietnam

        7. 2.2.4.7 Malaysia

        8. 2.2.4.8 Indonesia

        9. 2.2.4.9 Philippines

        10. 2.2.4.10 Thailand

        11. 2.2.4.11 Rest of Asia-Pacific

      5. 2.2.5 Middle East and Africa

        1. 2.2.5.1 Saudi Arabia

        2. 2.2.5.2 Iran

        3. 2.2.5.3 Egypt

        4. 2.2.5.4 Oman

        5. 2.2.5.5 South Africa

        6. 2.2.5.6 Rest of Middle East and Africa

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size FAQs

The Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 11.59 billion in 2024 and grow at a CAGR of 2.78% to reach USD 13.30 billion by 2029.

In 2024, the Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 11.59 billion.

DPP 4 Inhibitors Market Report Snapshots

DPP 4 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)